Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313488647> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4313488647 endingPage "1258" @default.
- W4313488647 startingPage "1255" @default.
- W4313488647 abstract "Introduction Immune checkpoint inhibitors (ICIs) have been widely used in the contemporary anticancer armamentarium. However, new side effects due to these agents have continued to emerge. Case report We describe herein a 71-year-old patient who received nivolumab as adjuvant therapy for malignant melanoma of the skin. He developed eosinophilia starting at 4 weeks of therapy. Eosinophilia increased progressively during the first six nivolumab cycles, then stabilized. Cycle-dependent increments were observed. Subsequently, the patient experienced well-known side effects of ICIs such as grade 1 diarrhea, arthralgias, and erythematous papular rash. Management and outcome Nivolumab was continued, and absolute eosinophil counts were monitored. Prednisone 10 mg PO daily was required for moderate gastroenteritis, dermatitis, and arthritis, which all subsequently improved. Eosinophil levels gradually downtrended after starting prednisone. Causality assessment between nivolumab and eosinophilia via adverse drug reaction (ADR) probability scale revealed a score of 9. Discussion Physicians and pharmacists need to be aware of this important side effect of ICI therapy. Eosinophilia in the context of ICI use has been previously reported in clinical trials. Our case is unique as eosinophilia was cumulative, showed increments every 8 weeks, and exhibited a trend toward cycle dependency. Extensive and expensive workup does not appear warranted, and simple monitoring of complete blood count is appropriate in most patients. Further studies are necessary to assess the true incidence, pattern, and severity of eosinophilia related to ICIs as well as its association with clinical outcomes." @default.
- W4313488647 created "2023-01-06" @default.
- W4313488647 creator A5001190634 @default.
- W4313488647 creator A5019650516 @default.
- W4313488647 creator A5039942974 @default.
- W4313488647 date "2023-01-03" @default.
- W4313488647 modified "2023-10-14" @default.
- W4313488647 title "Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma" @default.
- W4313488647 cites W2062868401 @default.
- W4313488647 cites W2067978628 @default.
- W4313488647 cites W2167751983 @default.
- W4313488647 cites W2546040128 @default.
- W4313488647 cites W2590359520 @default.
- W4313488647 cites W2922877541 @default.
- W4313488647 cites W2928377872 @default.
- W4313488647 cites W2991182014 @default.
- W4313488647 cites W3047063889 @default.
- W4313488647 cites W4205386712 @default.
- W4313488647 doi "https://doi.org/10.1177/10781552221148968" @default.
- W4313488647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36597613" @default.
- W4313488647 hasPublicationYear "2023" @default.
- W4313488647 type Work @default.
- W4313488647 citedByCount "0" @default.
- W4313488647 crossrefType "journal-article" @default.
- W4313488647 hasAuthorship W4313488647A5001190634 @default.
- W4313488647 hasAuthorship W4313488647A5019650516 @default.
- W4313488647 hasAuthorship W4313488647A5039942974 @default.
- W4313488647 hasConcept C120665830 @default.
- W4313488647 hasConcept C121332964 @default.
- W4313488647 hasConcept C121608353 @default.
- W4313488647 hasConcept C126322002 @default.
- W4313488647 hasConcept C16005928 @default.
- W4313488647 hasConcept C197934379 @default.
- W4313488647 hasConcept C2776042228 @default.
- W4313488647 hasConcept C2777037409 @default.
- W4313488647 hasConcept C2777129736 @default.
- W4313488647 hasConcept C2777658100 @default.
- W4313488647 hasConcept C2777701055 @default.
- W4313488647 hasConcept C2778570526 @default.
- W4313488647 hasConcept C2778720950 @default.
- W4313488647 hasConcept C2780030458 @default.
- W4313488647 hasConcept C502942594 @default.
- W4313488647 hasConcept C61511704 @default.
- W4313488647 hasConcept C71924100 @default.
- W4313488647 hasConceptScore W4313488647C120665830 @default.
- W4313488647 hasConceptScore W4313488647C121332964 @default.
- W4313488647 hasConceptScore W4313488647C121608353 @default.
- W4313488647 hasConceptScore W4313488647C126322002 @default.
- W4313488647 hasConceptScore W4313488647C16005928 @default.
- W4313488647 hasConceptScore W4313488647C197934379 @default.
- W4313488647 hasConceptScore W4313488647C2776042228 @default.
- W4313488647 hasConceptScore W4313488647C2777037409 @default.
- W4313488647 hasConceptScore W4313488647C2777129736 @default.
- W4313488647 hasConceptScore W4313488647C2777658100 @default.
- W4313488647 hasConceptScore W4313488647C2777701055 @default.
- W4313488647 hasConceptScore W4313488647C2778570526 @default.
- W4313488647 hasConceptScore W4313488647C2778720950 @default.
- W4313488647 hasConceptScore W4313488647C2780030458 @default.
- W4313488647 hasConceptScore W4313488647C502942594 @default.
- W4313488647 hasConceptScore W4313488647C61511704 @default.
- W4313488647 hasConceptScore W4313488647C71924100 @default.
- W4313488647 hasIssue "5" @default.
- W4313488647 hasLocation W43134886471 @default.
- W4313488647 hasLocation W43134886472 @default.
- W4313488647 hasOpenAccess W4313488647 @default.
- W4313488647 hasPrimaryLocation W43134886471 @default.
- W4313488647 hasRelatedWork W1982588557 @default.
- W4313488647 hasRelatedWork W2320683364 @default.
- W4313488647 hasRelatedWork W2323426201 @default.
- W4313488647 hasRelatedWork W2415224161 @default.
- W4313488647 hasRelatedWork W2908248310 @default.
- W4313488647 hasRelatedWork W3202117589 @default.
- W4313488647 hasRelatedWork W4212946376 @default.
- W4313488647 hasRelatedWork W4214692013 @default.
- W4313488647 hasRelatedWork W4229053615 @default.
- W4313488647 hasRelatedWork W4313488647 @default.
- W4313488647 hasVolume "29" @default.
- W4313488647 isParatext "false" @default.
- W4313488647 isRetracted "false" @default.
- W4313488647 workType "article" @default.